OPKO Health (OPK) Proxy Filing summary

Executive summary

• Amendment updates the Pay Versus Performance section to include required Inline XBRL tagging, with no other changes to content or compensation disclosures.

• Pay Versus Performance disclosure covers fiscal years 2020–2023, comparing CEO and NEO compensation, total shareholder return (TSR), peer group TSR, net income, and revenue.

• Revenue was selected as the key company-specific financial performance measure for 2023, though this may change in future years.

Executive compensation and say-on-pay

• Compensation for CEO and NEOs is detailed for 2020–2023, including both reported and “compensation actually paid” (CAP) figures, with reconciliation of equity adjustments.

• 2023 CAP increases were primarily due to a stock option grant to CEO and NEOs.

• Pay-for-performance metrics include adjusted operating income, revenue, and relative TSR; non-financial measures such as R&D pipeline progress are also considered.

• CAP for 2023 aligned with improved TSR and a smaller net income decline.

Voting matters and shareholder proposals

• No new voting matters or shareholder proposals are introduced in this amendment; the filing is limited to technical compliance updates.